Teva Pharmaceutical Industries (NYSE:TEVA) Cut to Buy at StockNews.com

Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Thursday.

A number of other research firms have also recently commented on TEVA. Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a report on Wednesday, July 10th. Barclays boosted their target price on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. UBS Group increased their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Finally, Jefferies Financial Group raised their price objective on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $18.89.

Teva Pharmaceutical Industries Stock Up 0.6 %

Shares of Teva Pharmaceutical Industries stock opened at $17.48 on Thursday. The stock’s 50-day moving average is $17.83 and its 200 day moving average is $16.35. Teva Pharmaceutical Industries has a one year low of $8.06 and a one year high of $19.08. The firm has a market cap of $19.80 billion, a price-to-earnings ratio of -42.63, a PEG ratio of 1.21 and a beta of 0.88. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.03. The firm had revenue of $4.16 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. Equities research analysts anticipate that Teva Pharmaceutical Industries will post 2.33 EPS for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 24,537 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the sale, the insider now owns 45,060 shares in the company, valued at $777,285. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.55% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sequoia Financial Advisors LLC grew its holdings in shares of Teva Pharmaceutical Industries by 0.7% in the second quarter. Sequoia Financial Advisors LLC now owns 111,575 shares of the company’s stock valued at $1,813,000 after acquiring an additional 826 shares in the last quarter. Edmond DE Rothschild Holding S.A. grew its stake in Teva Pharmaceutical Industries by 4.0% in the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 24,495 shares of the company’s stock valued at $346,000 after purchasing an additional 947 shares during the period. Oppenheimer & Co. Inc. increased its position in shares of Teva Pharmaceutical Industries by 9.6% during the 1st quarter. Oppenheimer & Co. Inc. now owns 13,522 shares of the company’s stock valued at $191,000 after purchasing an additional 1,180 shares during the last quarter. QRG Capital Management Inc. raised its stake in shares of Teva Pharmaceutical Industries by 0.8% during the 2nd quarter. QRG Capital Management Inc. now owns 144,938 shares of the company’s stock worth $2,355,000 after purchasing an additional 1,191 shares during the period. Finally, United Services Automobile Association boosted its holdings in shares of Teva Pharmaceutical Industries by 3.1% in the 2nd quarter. United Services Automobile Association now owns 41,159 shares of the company’s stock worth $669,000 after buying an additional 1,249 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.